

Giancarlo Pruneri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6206471/publications.pdf>

Version: 2024-02-01

395
papers

23,879
citations

9234

74
h-index

9553

142
g-index

414
all docs

414
docs citations

414
times ranked

26559
citing authors

#	ARTICLE	IF	CITATIONS
1	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. <i>Cancer Discovery</i> , 2022, 12, 90-107.	7.7	124
2	Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 1470.	1.6	10
3	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33
4	Mammographic density to predict response to neoadjuvant systemic breast cancer therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 775.	1.2	4
5	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100472.	1.5	2
6	Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model. <i>Frontiers in Oncology</i> , 2022, 12, 857515.	1.3	1
7	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5.	0.3	6
8	A three-gene signature based on <i>MYC</i> , <i>BCL-2</i> , and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2405-2416.	1.7	8
9	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. <i>Neuroendocrinology</i> , 2021, 111, 475-489.	1.2	19
10	STAT3 activation in HER2 α -positive breast cancers: Analysis of data from a large prospective trial. <i>International Journal of Cancer</i> , 2021, 148, 1529-1535.	2.3	6
11	The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model. <i>Tumori</i> , 2021, 107, 166-170.	0.6	5
12	Bioinformatic Pipelines to Analyze lncRNAs RNAseq Data. <i>Methods in Molecular Biology</i> , 2021, 2348, 55-69.	0.4	0
13	Transplantation of autologous extracellular vesicles for cancer-specific targeting. <i>Theranostics</i> , 2021, 11, 2034-2047.	4.6	32
14	Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 1409.	1.7	9
15	Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?. <i>PharmacoEconomics - Open</i> , 2021, 5, 285-298.	0.9	31
16	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor α -Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	3.2	4
17	Automated classification of cancer morphology from Italian pathology reports using Natural Language Processing techniques: A rule-based approach. <i>Journal of Biomedical Informatics</i> , 2021, 116, 103712.	2.5	21
18	Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. <i>ESMO Open</i> , 2021, 6, 100086.	2.0	31

#	ARTICLE	IF	CITATIONS
19	Multigene tests for breast cancer: the physician's perspective. <i>Oncotarget</i> , 2021, 12, 936-947.	0.8	9
20	64P Mammographic density to predict response to neoadjuvant chemotherapy for breast cancer. <i>Annals of Oncology</i> , 2021, 32, S49.	0.6	0
21	12P The RODILIA pilot study for molecular screening of patients with metaplastic breast cancer. <i>Annals of Oncology</i> , 2021, 32, S25-S26.	0.6	0
22	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. <i>Cancer Immunology Research</i> , 2021, 9, 825-837.	1.6	6
23	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	1.7	26
24	COVID-19 Pandemic: Huge Stress Test for Health System Could Be a Great Opportunity to Update the Workflow in a Modern Surgical Pathology. <i>Cancers</i> , 2021, 13, 3283.	1.7	4
25	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021, 511, 77-87.	3.2	22
26	Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples. <i>Clinical Epigenetics</i> , 2021, 13, 145.	1.8	15
27	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7154.	1.8	5
28	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. <i>Pathologica</i> , 2021, 113, 262-271.	1.3	13
29	94P ESCAT ranking of genomic alterations collected in the Italian Registry of Actionable Mutations. <i>Annals of Oncology</i> , 2021, 32, S397.	0.6	0
30	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	3.2	8
31	<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). <i>Haematologica</i> , 2021, 106, 2918-2926.	1.7	18
32	Use of PEAK PlasmaBlade in implant-based breast reconstruction and radiotherapy: new strategy to reduce complications. <i>Tumori</i> , 2021, , 0300891621110560.	0.6	1
33	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
34	Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. <i>Neuroendocrinology</i> , 2020, 110, 616-629.	1.2	43
35	Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 786-792.	1.2	1
36	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 112.	1.7	30

#	ARTICLE	IF	CITATIONS
37	Anticancer innovative therapy: Highlights from the ninth annual meeting. Cytokine and Growth Factor Reviews, 2020, 51, 1-9.	3.2	0
38	Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability. Cancers, 2020, 12, 3267.	1.7	22
39	Reply to E. Hindi. Journal of Clinical Oncology, 2020, 38, 3238-3240.	0.8	3
40	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. EBioMedicine, 2020, 56, 102793.	2.7	22
41	59P Primary tumour and circulating tumour cell (CTC) copy number alterations (CNAs) in triple negative breast cancer (TNBC) patients (pts) treated with neoadjuvant chemotherapy (NAC). Annals of Oncology, 2020, 31, S35-S36.	0.6	1
42	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. Genome Medicine, 2020, 12, 94.	3.6	11
43	175P Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2) positive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy. Annals of Oncology, 2020, 31, S312.	0.6	1
44	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research, 2020, 26, 6254-6265.	3.2	22
45	A new case of myelodysplastic syndrome associated with t(3;3)(q21;q26) and inv(11)(p15q22). Tumori, 2020, 106, NP18-NP22.	0.6	0
46	Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study. Breast Cancer Research and Treatment, 2020, 184, 723-731.	1.1	20
47	Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells, 2020, 9, 2644.	1.8	30
48	Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano. Tumori, 2020, 106, 193-202.	0.6	32
49	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15.	2.3	16
50	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16.	2.3	90
51	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
52	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. Cancers, 2020, 12, 617.	1.7	4
53	Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. Journal of Clinical Oncology, 2020, 38, 1591-1601.	0.8	50
54	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	2.1	142

#	ARTICLE	IF	CITATIONS
55	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. <i>Cancers</i> , 2020, 12, 1828.	1.7	1
56	Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2020, 31, 435-437.	0.6	1
57	Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. <i>Modern Pathology</i> , 2020, 33, 1065-1077.	2.9	3
58	ESOâ€“ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696.	0.6	172
59	Abstract P3-02-01: Fatty acid uptake as a potentially new resistance mechanism to anti-HER2 treatments in HER2-positive breast cancer. , 2020, , .		0
60	Abstract P3-08-22: The mutational landscape of cancer driver genes in matched primary ductal carcinoma in situ and recurrent ductal carcinoma in situ or recurrent invasive cancers. , 2020, , .		0
61	Abstract PD8-02: Phylogenetic reconstruction of advanced breast cancer reveals two different routes of metastatic dissemination associated with distinct clinical outcome. , 2020, , .		0
62	Abstract PD8-04: Ultra-deep multigene profiling of matched primary and metastatic hormone receptor positive breast cancer patients relapsed after adjuvant endocrine treatment reveals novel aberrations in the estrogen receptor pathway. , 2020, , .		1
63	OC-042 Genomic characterization of oral premalignant lesions to identify high-risk molecular clusters. <i>Radiotherapy and Oncology</i> , 2019, 132, 22.	0.3	0
64	MGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience. <i>Annals of Oncology</i> , 2019, 30, v272-v273.	0.6	0
65	Is MGMT methylation a new therapeutic target for biliary tract cancer?. <i>Annals of Oncology</i> , 2019, 30, v281.	0.6	1
66	Tumour-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study. <i>Annals of Oncology</i> , 2019, 30, v416.	0.6	1
67	Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference centre. <i>Annals of Oncology</i> , 2019, 30, v752-v753.	0.6	0
68	Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations. <i>Annals of Oncology</i> , 2019, 30, v800.	0.6	0
69	Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. <i>Nature Communications</i> , 2019, 10, 3840.	5.8	93
70	Circulating tumor DNA and disease recurrence in early stage breast cancer: From a case-control study to a prospective longitudinal trial. <i>Annals of Oncology</i> , 2019, 30, iii28-iii29.	0.6	3
71	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. <i>Cells</i> , 2019, 8, 605.	1.8	12
72	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroâ€“enteroâ€“pancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 217-226.	1.3	29

#	ARTICLE	IF	CITATIONS
73	Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment. <i>Cancer Medicine</i> , 2019, 8, 3012-3016.	1.3	9
74	SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ER \pm breast cancer. <i>Nature Communications</i> , 2019, 10, 2115.	5.8	42
75	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019, 46, 507-514.	0.6	9
76	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	1.6	38
77	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	1.6	22
78	Integration of transcriptional and mutational data simplifies the stratification of peripheral T α cell lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 628-634.	2.0	16
79	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
80	Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs. <i>British Journal of Cancer</i> , 2019, 120, 537-546.	2.9	37
81	ESR1 mutations in metastatic lobular breast cancer patients. <i>Npj Breast Cancer</i> , 2019, 5, 9.	2.3	26
82	WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. <i>Breast Cancer Research</i> , 2019, 21, 123.	2.2	31
83	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	1.7	16
84	P2.09-05 Clinical and Biological Characterization of Lung Enteric Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S770.	0.5	0
85	OA14.06 Hyperprogressive Disease in Advanced Non α Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, S245.	0.5	1
86	Antibody α Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non α small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	3.2	315
87	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. <i>Cancer Treatment Reviews</i> , 2019, 72, 45-55.	3.4	82
88	Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells. <i>Cancer Letters</i> , 2019, 442, 362-372.	3.2	14
89	Exploiting Fasting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019, 20, e413-e417.	1.1	27
90	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 1047-1051.	3.3	27

#	ARTICLE	IF	CITATIONS
91	Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection. <i>European Journal of Surgical Oncology</i> , 2019, 45, 755-760.	0.5	14
92	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	2.3	20
93	Abstract GS1-06: Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples. , 2019, ,		0
94	Fumarate hydratase expression in localized, radically-resected clear cell renal cell carcinoma and its association with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 620-620.	0.8	0
95	OR34-2 SREBP1 Drives KRT80-Dependent Cytoskeletal Changes and Invasive Behaviour in Endocrine-Resistant ER \pm Breast Cancer. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
96	The developmental origins of high grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17063-e17063.	0.8	0
97	Exploiting DNA repair alterations in metastatic pancreatic cancer (mPAC): Is MGMT methylation a new therapeutic target?. <i>Journal of Clinical Oncology</i> , 2019, 37, e15770-e15770.	0.8	0
98	CD205, a target antigen for a novel ADC: Evaluation of antigen expression on TNBC, pancreatic adenocarcinoma and bladder urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14726-e14726.	0.8	0
99	Gastroblastoma in Adulthoodâ€™ A Rarity among Rare Cancersâ€™ A Case Report and Review of the Literature. <i>Case Reports in Pathology</i> , 2019, 2019, 1-6.	0.2	8
100	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.	3.0	76
101	Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. <i>Nucleic Acids Research</i> , 2018, 46, 3817-3832.	6.5	31
102	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. <i>Endocrine-Related Cancer</i> , 2018, 25, 583-593.	1.6	77
103	Tumor infiltrating lymphocytes in early breast cancer. <i>Breast</i> , 2018, 37, 207-214.	0.9	108
104	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2018, 29, 162-169.	0.6	46
105	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
106	Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis. <i>Leukemia</i> , 2018, 32, 820-827.	3.3	22
107	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 551-557.	1.1	33
108	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	3.2	76

#	ARTICLE	IF	CITATIONS
109	Challenges for the pathologist. <i>Breast</i> , 2018, 41, S2-S3.	0.9	0
110	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	3.4	38
111	How to interpret the pathology report. <i>Breast</i> , 2018, 41, S6-S7.	0.9	0
112	Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?. <i>Annals of Oncology</i> , 2018, 29, viii430.	0.6	2
113	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1385-1393.	5.1	342
114	Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. <i>Nature Medicine</i> , 2018, 24, 1469-1480.	15.2	98
115	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e811-e814.	1.1	15
116	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. <i>Oncogene</i> , 2018, 37, 6463-6476.	2.6	15
117	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018, 52, 151-157.	4.3	108
118	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. <i>Npj Breast Cancer</i> , 2018, 4, 23.	2.3	26
119	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	0.6	32
120	Prognostic and predictive role of fumarate hydratase in metastatic clear cell renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 617-617.	0.8	0
121	Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation. , 2018, , .		3
122	Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified. <i>Blood</i> , 2018, 132, 4115-4115.	0.6	0
123	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER± metastatic breast cancer. <i>Nature Genetics</i> , 2017, 49, 444-450.	9.4	77
124	Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box. <i>Cancer Treatment Reviews</i> , 2017, 55, 1-9.	3.4	21
125	A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 363-370.	0.7	56
126	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. <i>Breast</i> , 2017, 34, 83-88.	0.9	22

#	ARTICLE	IF	CITATIONS
127	Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers. <i>EMBO Molecular Medicine</i> , 2017, 9, 655-671.	3.3	33
128	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2017, 28, 321-328.	0.6	72
129	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	0.9	203
130	Mutations targeting the coagulation pathway are enriched in brain metastases. <i>Scientific Reports</i> , 2017, 7, 6573.	1.6	10
131	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	530
132	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immuno-oncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
133	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 164-171.	1.3	7
134	Prognostic and Predictive Role of Genetic Signatures. , 2017, , 121-131.		0
135	Over-using chemotherapy in the adjuvant setting. <i>Breast</i> , 2017, 31, 303-308.	0.9	9
136	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2017, 28, v68.	0.6	3
137	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	11
138	Prognostic value of tumor-infiltrating lymphocytes in small HER2-positive breast cancer. <i>Annals of Oncology</i> , 2017, 28, vi32.	0.6	0
139	PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples. <i>Clinical Epigenetics</i> , 2017, 9, 69.	1.8	17
140	Metabolic shifts in residual breast cancer drive tumor recurrence. <i>Journal of Clinical Investigation</i> , 2017, 127, 2091-2105.	3.9	128
141	Abstract P3-04-04: Detection of ESR1 mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients. , 2017, , .		0
142	Abstract P1-05-17: Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling. , 2017, , .		0
143	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 575-575.	0.8	1
144	Abstract 1452: Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
145	A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT) Tj ETQq1 1 Oncology, 2016, 34, 177-183.	0.784314 0.8	48
146	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 2016, 158, 323-331.	1.1	100
147	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
148	Polycomb dysregulation in gliomagenesis targets a Zfp423-dependent differentiation network. Nature Communications, 2016, 7, 10753.	5.8	23
149	Mass-spectrometry analysis of histone post-translational modifications in pathology tissue using the PAT-H-MS approach. Data in Brief, 2016, 7, 188-194.	0.5	6
150	Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. International Journal of Cancer, 2016, 139, 2127-2134.	2.3	30
151	Genetic code expansion for multiprotein complex engineering. Nature Methods, 2016, 13, 997-1000.	9.0	63
152	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. Tumori, 2016, 102, 108-113.	0.6	4
153	Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. Current Opinion in Oncology, 2016, 28, 476-483.	1.1	6
154	Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncology, 2016, 12, 2001-2008.	1.1	6
155	A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients. Cancer Prevention Research, 2016, 9, 349-356.	0.7	14
156	Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1872-1881.	0.8	249
157	A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. Cancer Prevention Research, 2016, 9, 89-95.	0.7	35
158	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Annals of Oncology, 2016, 27, 249-256.	0.6	125
159	Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples. Molecular and Cellular Proteomics, 2016, 15, 866-877.	2.5	41
160	Abstract P2-08-02: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM). Cancer Research, 2016, 76, P2-08-02-P2-08-02.	0.4	1
161	RNAi screens identify CHD4 as an essential gene in breast cancer growth. Oncotarget, 2016, 7, 80901-80915.	0.8	37
162	Abstract S1-02: Lymphocytic infiltration in invasive lobular breast cancer. Cancer Research, 2016, 76, S1-02-S1-02.	0.4	1

#	ARTICLE	IF	CITATIONS
163	Abstract P1-05-01: The epithelial to mesenchymal transition: Identifying a signature of recurrence in ductal carcinoma in situ. , 2016, , .		0
164	Abstract 1788: Benefit of low-dose tamoxifen in a large, single-institution cohort of high-risk ER-positive DCIS. , 2016, , .		0
165	Abstract CT122: A presurgical study of lecithin formulation of green tea extract in women with early breast cancer. , 2016, , .		0
166	Core needle biopsy as a front line diagnostic approach for lymphoma patients. Hematological Oncology, 2015, 33, 247-249.	0.8	15
167	Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma â€œ a case report. Scientific Reports, 2015, 5, 14829.	1.6	2
168	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Annals of Oncology, 2015, 26, 873-879.	0.6	151
169	Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. Antioxidants and Redox Signaling, 2015, 23, 15-29.	2.5	13
170	Genomic hallmarks of invasive lobular breast carcinoma and their clinical relevance. Annals of Oncology, 2015, 26, vi3.	0.6	0
171	Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Annals of Oncology, 2015, 26, 682-687.	0.6	51
172	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast, 2015, 24, 290-293.	0.9	27
173	RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Research, 2015, 17, 24.	2.2	149
174	Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial. Cancer Prevention Research, 2015, 8, 888-894.	0.7	23
175	Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. Clinical Breast Cancer, 2015, 15, e237-e241.	1.1	13
176	7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages. Nature Genetics, 2015, 47, 132-141.	9.4	108
177	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of Oncology, 2015, 26, 259-271.	0.6	2,122
178	Chlorambucilâ€“rituximab as firstâ€“line therapy in patients affected by follicular nonâ€“Hodgkin's lymphoma: a retrospective singleâ€“centre study. Hematological Oncology, 2015, 33, 129-135.	0.8	11
179	Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series. International Journal of Clinical Oncology, 2015, 20, 90-94.	1.0	2
180	Abstract S2-05: Characterization and clinical relevance of the genomic alterations defining lobular breast cancer. , 2015, , .		1

#	ARTICLE	IF	CITATIONS
181	DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through notch hyper-activation. <i>Oncotarget</i> , 2015, 6, 22467-22479.	0.8	33
182	Abstract P5-12-02: Metformin decreases Ki67 in HER2+ve ductal carcinoma in situ in a window of opportunity trial. , 2015, , .		0
183	Abstract P4-11-15: Risk stratification within luminal B breast cancer using a second generation prognostic RNA signature. , 2015, , .		0
184	Abstract P6-01-01: RANK/RANKL expression by immunohistochemistry (IHC) in young breast cancer (BC) patients and during pregnancy: Association with clinicopathologic features, gene expression profiles and patient outcome. , 2015, , .		0
185	Efficacy of ⁹⁰ Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. <i>Hematological Oncology</i> , 2014, 32, 10-15.	0.8	24
186	Prevalence of <i>Chromobacter xylosoxidans</i> in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. <i>British Journal of Haematology</i> , 2014, 164, 804-810.	1.2	54
187	Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. <i>Annals of Oncology</i> , 2014, 25, 618-623.	0.6	28
188	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. <i>Breast Cancer Research</i> , 2014, 16, R65.	2.2	138
189	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 81-90.	1.1	65
190	Prevalence and Clinicopathologic Correlates of O6-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs. <i>Clinical Breast Cancer</i> , 2014, 14, 285-290.	1.1	10
191	Functional characterization of a novel FGFR1OP&RET rearrangement in hematopoietic malignancies. <i>Molecular Oncology</i> , 2014, 8, 221-231.	2.1	27
192	Reply to letter by leni et al.. <i>European Journal of Cancer</i> , 2014, 50, 1038-1039.	1.3	0
193	Outcome of Male Breast Cancer: A Matched Single-Institution Series. <i>Clinical Breast Cancer</i> , 2014, 14, 371-377.	1.1	32
194	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet</i> , The, 2014, 383, 2127-2135.	6.3	1,701
195	Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression. <i>Clinical Breast Cancer</i> , 2014, 14, 258-264.	1.1	51
196	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014, 50, 277-289.	1.3	212
197	Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids. <i>British Journal of Cancer</i> , 2014, 110, 1244-1249.	2.9	12
198	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014, 21, 545-554.	1.6	58

#	ARTICLE	IF	CITATIONS
199	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 573-582.	1.1	9
200	A presurgical study of oral silybin-phosphatidylcholine in patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2580-2580.	0.8	0
201	Differential effects of metformin on breast cancer proliferation according to insulin resistance and tumor subtype in a presurgical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 599-599.	0.8	0
202	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 382.	0.6	5
203	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 372.	0.6	2
204	Immediate breast reconstruction with expander in pregnant breast cancer patients. <i>Breast</i> , 2013, 22, 657-660.	0.9	46
205	The clinical relevance of micropapillary carcinoma of the breast: a caseâ€“control study. <i>Histopathology</i> , 2013, 63, 217-224.	1.6	53
206	A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R47.	2.2	23
207	Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. <i>Annals of Oncology</i> , 2013, 24, 661-668.	0.6	91
208	Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4â€“9 positive lymph nodes. <i>Breast</i> , 2013, 22, 682-690.	0.9	47
209	Pathological features and survival outcomes of very young patients with early breast cancer: How much is â€œvery youngâ€?. <i>Breast</i> , 2013, 22, 1046-1051.	0.9	32
210	Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. <i>Clinical Breast Cancer</i> , 2013, 13, 31-39.	1.1	128
211	Immunohistochemically Defined Subtypes and Outcome of Apocrine Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 95-102.	1.1	52
212	The effect of metformin on apoptosis in a breast cancer presurgical trial. <i>British Journal of Cancer</i> , 2013, 109, 2792-2797.	2.9	72
213	Cell Reprogramming Requires Silencing of a Core Subset of Polycomb Targets. <i>PLoS Genetics</i> , 2013, 9, e1003292.	1.5	59
214	Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. <i>Annals of Oncology</i> , 2013, 24, 1859-1866.	0.6	18
215	Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer. <i>Cancer Research</i> , 2013, 73, 5880-5891.	0.4	91
216	NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. <i>Leukemia</i> , 2013, 27, 2248-2251.	3.3	41

#	ARTICLE	IF	CITATIONS
217	Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. <i>British Journal of Cancer</i> , 2013, 108, 1593-1601.	2.9	38
218	Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. <i>Acta Oncologica</i> , 2013, 52, 1649-1656.	0.8	56
219	Metformin effects on cancer adjacent breast preneoplasia in a randomized pre-surgical trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1517-1517.	0.8	0
220	Management of breast cancer during pregnancy: Results of a large registry from a single institution.. <i>Journal of Clinical Oncology</i> , 2013, 31, 589-589.	0.8	0
221	Outcome and clinical biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. <i>Annals of Oncology</i> , 2012, 23, 2884-2890.	0.6	2
222	The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study. <i>Acta Oncologica</i> , 2012, 51, 653-661.	0.8	65
223	Estrogen Receptor in Breast Ductal Carcinoma in Situ: Good Cop, Bad Cop?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1384-1386.	0.8	5
224	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2593-2600.	0.8	218
225	Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. <i>Lancet, The</i> , 2012, 379, 432-444.	6.3	1,753
226	Spontaneous Cell Fusion of Acute Leukemia Cells and Macrophages Observed in Cells with Leukemic Potential. <i>Neoplasia</i> , 2012, 14, 1057-1064.	2.3	24
227	Outcome of special types of luminal breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1428-1436.	0.6	99
228	The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression. <i>Cancer Research</i> , 2012, 72, 325-334.	0.4	138
229	Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 131-137.	1.1	35
230	Abstract PD03-01: EFFECT OF METFORMIN ON APOPTOSIS IN A PRESURGICAL TRIAL IN NON-DIABETIC PATIENTS WITH BREAST CANCER. , 2012, , .		2
231	A meta-analysis of receptor status discordance between primary breast cancer and metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 546-546.	0.8	1
232	Abstract 2664: Biological relevance of CYP2D6 phenotype and low dose tamoxifen activity within a randomized phase II pre-surgical trial.. , 2012, , .		0
233	Abstract 3561: Effects of metformin on markers of insulin resistance and on breast cancer proliferation: The putative role of IGFBP-1 as a predictive biomarker. , 2012, , .		0
234	Dual effects of metformin on breast cancer proliferation in a randomized trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 519-519.	0.8	6

#	ARTICLE	IF	CITATIONS
235	Abstract PD04-07: The Ki-67 labeling index predicts the risk of recurrence of DIN patients treated with radiotherapy following breast conserving surgery.. , 2012, , .		0
236	Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer. , 2012, , .		0
237	Abstract PD06-06: RELATIONSHIP BETWEEN MOLECULAR SUBTYPE AND CHANGE IN KI-67 IN THE PLACEBO ARMS OF WINDOW OF OPPORTUNITY TRIALS. , 2012, , .		0
238	Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. <i>Annals of Oncology</i> , 2011, 22, 582-587.	0.6	72
239	The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. <i>Leukemia</i> , 2011, 25, 814-820.	3.3	30
240	Rituximab in Hodgkin lymphoma: Is the target always a hit?. <i>Cancer Treatment Reviews</i> , 2011, 37, 385-390.	3.4	38
241	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Annals of Oncology</i> , 2011, 22, 2227-2233.	0.6	103
242	The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. <i>Blood</i> , 2011, 117, 6617-6626.	0.6	22
243	Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 713-720.	1.1	98
244	In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. <i>Hematological Oncology</i> , 2011, 29, 164-166.	0.8	3
245	Lapatinib Activity in Premalignant Lesions and HER-2-Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial. <i>Cancer Prevention Research</i> , 2011, 4, 1181-1189.	0.7	52
246	Tissue Microarrays in Diffuse Large B-Cell Lymphomas. <i>International Journal of Surgical Pathology</i> , 2011, 19, 417-424.	0.4	1
247	Metaplastic carcinoma with extensive dendritic cell differentiation: a previously unrecognized type of triple-negative breast cancer. <i>Annals of Oncology</i> , 2011, 22, 2531-2532.	0.6	1
248	Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.. <i>Journal of Clinical Oncology</i> , 2011, 29, 546-546.	0.8	1
249	CD45-CD34+ Endothelial Progenitor Cells (EPCs) from Human Adipose Tissue Promote Tumor Growth and Metastases. <i>Blood</i> , 2011, 118, 2208-2208.	0.6	0
250	Efficacy of 90Yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,. <i>Blood</i> , 2011, 118, 3713-3713.	0.6	0
251	Potential Pathogenetic Role of <i>Achromobacter</i> (<i>Alcaligenes</i>) <i>Xylosoxidans</i> in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2011, 118, 880-880.	0.6	2
252	ecancermedalscience. <i>Ecancermedalscience</i> , 2010, 4, 184.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Synchronous Primary Lung Cancer, Breast Cancer Recurrence, and Mediastinal Silicon-Induced Lymphadenitis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 560-561.	0.5	0
254	A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. <i>Blood</i> , 2010, 116, 2096-2102.	0.6	35
255	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 689-699.	1.1	65
256	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. <i>BMC Cancer</i> , 2010, 10, 644.	1.1	20
257	Syk expression patterns differ among B-cell lymphomas. <i>Leukemia Research</i> , 2010, 34, e243-e245.	0.4	3
258	Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. <i>British Journal of Haematology</i> , 2010, 150, 229-232.	1.2	2
259	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47
260	Rituximab and Subcutaneous 2-Chloro-2-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2233-2238.	0.8	56
261	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1974-1981.	0.6	202
262	Is there a role for 'modified VAD' in the treatment of multiple myeloma?. <i>Ecancermedicalsecience</i> , 2010, 3, 136.	0.6	0
263	Bona Fide Primary Merkel Cell Carcinoma of an Intraparotid Lymph Node in a HIV-Positive Patient. <i>International Journal of Surgical Pathology</i> , 2010, 18, 406-408.	0.4	8
264	Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. <i>Leukemia and Lymphoma</i> , 2010, 51, 1485-1493.	0.6	11
265	Abstract PD03-02: A Randomized Pre-Surgical Trial of Metformin in Breast Cancer. Preliminary Feasibility and Safety Results. , 2010, , .		3
266	Randomized phase II trial of preoperative lapatinib versus placebo in HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2010, 28, 576-576.	0.8	3
267	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Journal of Clinical Oncology</i> , 2010, 28, CRA1008-CRA1008.	0.8	17
268	PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2010, 116, 1770-1770.	0.6	0
269	Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma. <i>Blood</i> , 2010, 116, 3956-3956.	0.6	0
270	Management of Anaplastic Large-Cell Lymphoma During Pregnancy. <i>Journal of Clinical Oncology</i> , 2009, 27, e75-e77.	0.8	8

#	ARTICLE	IF	CITATIONS
271	Rituximab in Lymphocyte-Predominant Hodgkin Disease. <i>Oncology</i> , 2009, 76, 26-29.	0.9	14
272	Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2009, 20, 1993-1999.	0.6	90
273	A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. <i>Annals of Oncology</i> , 2009, 20, 1178-1184.	0.6	36
274	0071 The 70-gene MammaPrint profile allows to identify a subgroup of very good-prognostic patients with primary breast cancer and 4-9 positive lymph nodes. <i>Breast</i> , 2009, 18, S36.	0.9	1
275	The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 295-302.	1.1	260
276	Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 359-369.	1.1	86
277	Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 385-394.	1.1	31
278	Magnetic resonance imaging of primary breast lymphoma. <i>Radiologia Medica</i> , 2009, 114, 915-924.	4.7	16
279	Plasmablastic lymphoma: a review. <i>Oral Diseases</i> , 2009, 15, 38-45.	1.5	102
280	Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. <i>European Journal of Cancer</i> , 2009, 45, 1201-1208.	1.3	36
281	BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. <i>Human Pathology</i> , 2009, 40, 645-652.	1.1	96
282	Confocal laser endomicroscopy diagnosis of gastric adenocarcinoma in a patient treated for gastric diffuse large-B-cell lymphoma. <i>Digestive and Liver Disease</i> , 2009, 41, 447-449.	0.4	7
283	Uterine carcinosarcoma metastatic to the lung as large-cell neuroendocrine carcinoma with synchronous sarcoid granulomatosis. <i>Lung Cancer</i> , 2009, 64, 371-377.	0.9	8
284	43LBA Combining genomic profiling (70-gene MammaPrint) with nodal status allows to classify patients with primary breast cancer and positive lymph nodes (1-9) into very distinct prognostic subgroups that could help tailor treatment strategies.. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 19.	2.2	0
285	Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. <i>Leukemia and Lymphoma</i> , 2009, 50, 925-931.	0.6	27
286	9207 Efficacy of 90Yttrium-ibritumomab tiuxetan in extranodal marginal-zone lymphoma. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 562.	2.2	0
287	Response to Neo-Adjuvant Chemotherapy for Colorectal Cancer Liver Metastases: A Key for Improving Survival?. <i>Ecancermedalscience</i> , 2009, 1, 58.	0.6	0
288	Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP.. <i>Blood</i> , 2009, 114, 3957-3957.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.. Blood, 2009, 114, 3754-3754.	0.6	0
290	Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemotherapy and Pharmacology, 2008, 61, 965-971.	1.1	20
291	Human acute leukemia cells injected in NOD/LtSz- $\beta 2\text{M}^{-/-}$ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. International Journal of Cancer, 2008, 123, 2222-2227.	2.3	155
292	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leukemia Research, 2008, 32, 1628-1632.	0.4	1
293	Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. Critical Reviews in Oncology/Hematology, 2008, 65, 1-7.	2.0	86
294	The 70-gene profile is a powerful predictor of disease outcome in breast cancer patients with ≥ 3 positive lymph nodes. European Journal of Cancer, Supplement, 2008, 6, 195.	2.2	0
295	Extramedullary Myeloid Sarcoma of the Breast. Journal of Clinical Oncology, 2008, 26, 4041-4043.	0.8	13
296	Efficacy of 90Y Ibritumomab-Tiuxetan Treatment in a Case of Resistant Gastric Malt Non Hodgkin's Lymphoma. Ecanermedscience, 2008, 2, 79.	0.6	1
297	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Annals of Oncology, 2008, 19, 233-241.	0.6	203
298	Lymph Node Metastases of Merkel Cell Carcinoma from Unknown Primary Site: Report of Three Cases. Tumori, 2008, 94, 758-761.	0.6	22
299	Human acute leukemia cells injected in NOD/LtSz-scid/IL-2R $\beta^{-/-}$ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. , 2008, 123, 2222.		1
300	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. Blood, 2008, 112, 478-478.	0.6	0
301	Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma. Blood, 2008, 112, 3063-3063.	0.6	1
302	Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano. Blood, 2008, 112, 5016-5016.	0.6	5
303	Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Annals of Oncology, 2007, 18, 1632-1640.	0.6	92
304	Chlorambucil + rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis. Leukemia and Lymphoma, 2007, 48, 437-438.	0.6	2
305	Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT type. Hematological Oncology, 2007, 25, 184-188.	0.8	8
306	Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. British Journal of Cancer, 2007, 97, 802-808.	2.9	67

#	ARTICLE	IF	CITATIONS
307	Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).. Blood, 2007, 110, 4499-4499.	0.6	4
308	Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.. Blood, 2007, 110, 5116-5116.	0.6	0
309	Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin's Lymphoma (HL): A Single Centre Experience.. Blood, 2007, 110, 4463-4463.	0.6	0
310	Report on a Case of Breast Sarcoma Metastatic to the Axillary Lymph Nodes. Tumori, 2006, 92, 188-190.	0.6	3
311	Report on a Case of Pure Cribriform Carcinoma of the Breast with Internal Mammary Node Metastasis: Description of the Case and Review of the Literature. Tumori, 2006, 92, 241-243.	0.6	7
312	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood, 2006, 108, 452-459.	0.6	242
313	EFFECT OF RESECTION AND OUTCOME IN PATIENTS WITH RETROPERITONEAL SARCOMA. ANZ Journal of Surgery, 2006, 76, 462-466.	0.3	9
314	Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. British Journal of Haematology, 2006, 132, 303-316.	1.2	169
315	Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. British Journal of Haematology, 2006, 134, 27-36.	1.2	56
316	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology, 2006, 48, 529-535.	1.6	14
317	Surgical outcomes after total mesorectal excision for rectal cancer. Journal of Surgical Oncology, 2006, 94, 182-193.	0.8	40
318	Delocalization and Destabilization of the Arf Tumor Suppressor by the Leukemia-Associated NPM Mutant. Cancer Research, 2006, 66, 3044-3050.	0.4	138
319	Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Annals of Oncology, 2006, 17, 1497-1503.	0.6	72
320	Efficacy of 90Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin's Lymphoma.. Blood, 2006, 108, 2771-2771.	0.6	2
321	In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.. Blood, 2006, 108, 2520-2520.	0.6	25
322	Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?.. Blood, 2006, 108, 2037-2037.	0.6	5
323	SP4, a Novel Anti-Cyclin D1 Rabbit Monoclonal Antibody, Is a Highly Sensitive Probe for Identifying Mantle Cell Lymphomas Bearing the t(11;14)(q13;q32) Translocation. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 318-322.	0.6	14
324	Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy. Annals of Surgery, 2005, 241, 319-325.	2.1	223

#	ARTICLE	IF	CITATIONS
325	Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement. <i>Histopathology</i> , 2005, 46, 464-466.	1.6	7
326	Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. <i>Oncogene</i> , 2005, 24, 2461-2473.	2.6	118
327	Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. <i>Modern Pathology</i> , 2005, 18, 1277-1282.	2.9	89
328	Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. <i>Oral Oncology</i> , 2005, 41, 147-155.	0.8	73
329	Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. <i>Cancer</i> , 2005, 103, 492-500.	2.0	191
330	Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003. <i>International Journal of Colorectal Disease</i> , 2005, 20, 221-230.	1.0	22
331	The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. <i>Journal of Pathology</i> , 2005, 206, 337-345.	2.1	39
332	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1979-1983.	0.8	265
333	Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 232-233.	0.8	5
334	Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2005, 23, 1379-1389.	0.8	153
335	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2005, 46, 1345-1351.	0.6	38
336	Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas. <i>Blood</i> , 2005, 106, 1469-1469.	0.6	0
337	High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis. <i>Blood</i> , 2005, 106, 5506-5506.	0.6	0
338	Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors. <i>Clinical Cancer Research</i> , 2004, 10, 6622-6628.	3.2	333
339	Assessing Tumor Angiogenesis. <i>Cancer Research</i> , 2004, 64, 4373-4377.	0.4	83
340	Association Between p53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 2004, 130, 303.	1.5	15
341	ChlVPP/ABVVP, a first line "hybrid" combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. <i>British Journal of Haematology</i> , 2004, 125, 584-589.	1.2	10
342	Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. <i>EMBO Journal</i> , 2004, 23, 1144-1154.	3.5	109

#	ARTICLE	IF	CITATIONS
343	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. <i>Modern Pathology</i> , 2004, 17, 1513-1520.	2.9	20
344	Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. <i>European Journal of Haematology</i> , 2004, 72, 264-267.	1.1	20
345	Interlaminar astroglial processes in the cerebral cortex of great apes. <i>Anatomy and Embryology</i> , 2004, 208, 215-8.	1.5	17
346	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. <i>International Journal of Cancer</i> , 2004, 112, 71-77.	2.3	16
347	Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients. <i>Journal of Surgical Oncology</i> , 2004, 85, 123-128.	0.8	33
348	Prognostic Significance of P27 and Cyclin D1 Co-Expression in Laryngeal Squamous Cell Carcinoma: Possible Target for Novel Therapeutic Strategies. <i>Journal of Chemotherapy</i> , 2004, 16, 3-6.	0.7	7
349	Gene Expression Profiling of Plasma Cell Dyscrasias: The Role of IGH Translocations in the Heterogeneity of Multiple Myeloma.. <i>Blood</i> , 2004, 104, 4845-4845.	0.6	0
350	Bronchial-Associated Lymphoid Tissue (BALT) Lymphoma: A Multicenter Retrospective Analysis.. <i>Blood</i> , 2004, 104, 4583-4583.	0.6	0
351	Basaloid cell carcinoma of the prostate. Case report and review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 787-791.	1.4	29
352	Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: Identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. <i>International Journal of Cancer</i> , 2003, 106, 288-291.	2.3	28
353	Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. <i>British Journal of Haematology</i> , 2003, 120, 695-698.	1.2	18
354	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. <i>Journal of Pathology</i> , 2003, 200, 596-601.	2.1	8
355	Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. <i>Modern Pathology</i> , 2003, 16, 886-892.	2.9	22
356	Intraepidermal cells of pagetâ€™s carcinoma of the breast can be genetically different from those of the underlying carcinoma. <i>Human Pathology</i> , 2003, 34, 1321-1330.	1.1	53
357	Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation. <i>Human Pathology</i> , 2003, 34, 41-47.	1.1	19
358	Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant Program. <i>Leukemia and Lymphoma</i> , 2003, 44, 299-302.	0.6	7
359	Ectopic Breast Tissue as a Possible Cause of False-Positive Axillary Sentinel Lymph Node Biopsies. <i>American Journal of Surgical Pathology</i> , 2003, 27, 513-518.	2.1	83
360	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003, 102, 2741-2745.	0.6	391

#	ARTICLE	IF	CITATIONS
361	Axillary Sentinel Lymph Node Biopsy in Patients With Pure Ductal Carcinoma In Situ of the Breast. Archives of Surgery, 2003, 138, 309.	2.3	142
362	Circulating Endothelial Cells as a Novel Marker of Angiogenesis. Advances in Experimental Medicine and Biology, 2003, 522, 83-97.	0.8	82
363	Sentinel Lymph Node Biopsy Performed With Local Anesthesia in Patients With Early-Stage Breast Carcinoma. Archives of Surgery, 2002, 137, 1157.	2.3	28
364	Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma. Journal of Laryngology and Otology, 2002, 116, 610-612.	0.4	1
365	In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. Experimental Hematology, 2002, 30, 905-914.	0.2	34
366	Follicular dendritic cell sarcoma of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 441, 194-199.	1.4	28
367	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. British Journal of Haematology, 2002, 118, 817-820.	1.2	87
368	p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?. Journal of Pathology, 2002, 198, 100-109.	2.1	134
369	p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity. Laboratory Investigation, 2002, 82, 1327-1334.	1.7	40
370	CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Research, 2002, 62, 3106-12.	0.4	166
371	Monoclonal proliferation of germinal center cells (incipient follicular lymphoma) in an axillary lymph node of a melanoma patient. Human Pathology, 2001, 32, 1410-1413.	1.1	20
372	Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 2001, 97, 3658-3661.	0.6	401
373	Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer, 2001, 92, 1378-1384.	2.0	216
374	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. International Journal of Cancer, 2001, 92, 666-670.	2.3	27
375	Immunoreactivity for p27KIP1 and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. International Journal of Cancer, 2001, 94, 599-604.	2.3	21
376	Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. , 2000, 22, 234-240.		50
377	Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. Leukemia, 2000, 14, 1477-1482.	3.3	44
378	Endostatin induces tumor stabilization after chemo- or ANTI-CD20 therapy of high-grade non-hodgkin's lymphoma (Nhl). Experimental Hematology, 2000, 28, 66-67.	0.2	0

#	ARTICLE	IF	CITATIONS
379	The thin red line. <i>Experimental Hematology</i> , 2000, 28, 993-1000.	0.2	77
380	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 96, 282-287.	0.6	84
381	Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14). <i>American Journal of Pathology</i> , 2000, 156, 1505-1513.	1.9	72
382	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 96, 282-287.	0.6	8
383	Clinical Relevance of Expression of the CIP/KIP Cell-Cycle Inhibitors p21 and p27 in Laryngeal Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 3150-3159.	0.8	75
384	Angiogenesis in myelodysplastic syndromes. <i>British Journal of Cancer</i> , 1999, 81, 1398-1401.	2.9	260
385	Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. , 1998, 79, 263-268.		46
386	Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. , 1998, 34, 113-120.		45
387	Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow. <i>Annals of Hematology</i> , 1998, 76, 81-83.	0.8	25
388	The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx. <i>Journal of Laryngology and Otology</i> , 1998, 112, 455-459.	0.4	35
389	Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3069-3077.	0.8	70
390	Clinical relevance of p53 and bcl-2 protein overexpression in laryngeal squamous cell carcinoma. <i>International Journal of Cancer</i> , 1998, 79, 263-268.	2.3	2
391	Cyclin D1 protein expression is related to clinical progression in laryngeal squamous cell carcinomas. <i>Journal of Laryngology and Otology</i> , 1997, 111, 622-626.	0.4	21
392	Polysialylated N-CAM, chromogranin A and B, and secretogranin II in neuroendocrine tumours of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 430, 455-460.	1.4	17
393	Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas. , 1997, 79, 1114-1121.		50
394	p53 Protein expression in laryngeal squamous cell carcinomas bearing wild-type and mutated p53 gene. <i>Histopathology</i> , 1996, 28, 513-519.	1.6	14
395	p53 and cyclin D1 protein expression in glottic laryngeal squamous cell carcinomas involving the anterior commissure (pT1bNOMO). <i>International Journal of Oncology</i> , 1996, 9, 553-7.	1.4	1